T

TScan Therapeutics Inc
NASDAQ:TCRX

Watchlist Manager
TScan Therapeutics Inc
NASDAQ:TCRX
Watchlist
Price: 4.26 USD 8.12% Market Closed
Market Cap: 225.7m USD
Have any thoughts about
TScan Therapeutics Inc?
Write Note

Intrinsic Value

TCRX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one TCRX stock under the Base Case scenario is 1.53 USD. Compared to the current market price of 4.26 USD, TScan Therapeutics Inc is Overvalued by 64%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

TCRX Intrinsic Value
1.53 USD
Overvaluation 64%
Intrinsic Value
Price
T
Base Case Scenario

Valuation Backtest
TScan Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for TCRX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about TCRX?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about TScan Therapeutics Inc

Provide an overview of the primary business activities
of TScan Therapeutics Inc.

What unique competitive advantages
does TScan Therapeutics Inc hold over its rivals?

What risks and challenges
does TScan Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in TScan Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for TScan Therapeutics Inc.

Provide P/S
for TScan Therapeutics Inc.

Provide P/E
for TScan Therapeutics Inc.

Provide P/OCF
for TScan Therapeutics Inc.

Provide P/FCFE
for TScan Therapeutics Inc.

Provide P/B
for TScan Therapeutics Inc.

Provide EV/S
for TScan Therapeutics Inc.

Provide EV/GP
for TScan Therapeutics Inc.

Provide EV/EBITDA
for TScan Therapeutics Inc.

Provide EV/EBIT
for TScan Therapeutics Inc.

Provide EV/OCF
for TScan Therapeutics Inc.

Provide EV/FCFF
for TScan Therapeutics Inc.

Provide EV/IC
for TScan Therapeutics Inc.

Show me price targets
for TScan Therapeutics Inc made by professional analysts.

What are the Revenue projections
for TScan Therapeutics Inc?

How accurate were the past Revenue estimates
for TScan Therapeutics Inc?

What are the Net Income projections
for TScan Therapeutics Inc?

How accurate were the past Net Income estimates
for TScan Therapeutics Inc?

What are the EPS projections
for TScan Therapeutics Inc?

How accurate were the past EPS estimates
for TScan Therapeutics Inc?

What are the EBIT projections
for TScan Therapeutics Inc?

How accurate were the past EBIT estimates
for TScan Therapeutics Inc?

Compare the revenue forecasts
for TScan Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of TScan Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of TScan Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of TScan Therapeutics Inc compared to its peers.

Compare the P/E ratios
of TScan Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing TScan Therapeutics Inc with its peers.

Analyze the financial leverage
of TScan Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for TScan Therapeutics Inc.

Provide ROE
for TScan Therapeutics Inc.

Provide ROA
for TScan Therapeutics Inc.

Provide ROIC
for TScan Therapeutics Inc.

Provide ROCE
for TScan Therapeutics Inc.

Provide Gross Margin
for TScan Therapeutics Inc.

Provide Operating Margin
for TScan Therapeutics Inc.

Provide Net Margin
for TScan Therapeutics Inc.

Provide FCF Margin
for TScan Therapeutics Inc.

Show all solvency ratios
for TScan Therapeutics Inc.

Provide D/E Ratio
for TScan Therapeutics Inc.

Provide D/A Ratio
for TScan Therapeutics Inc.

Provide Interest Coverage Ratio
for TScan Therapeutics Inc.

Provide Altman Z-Score Ratio
for TScan Therapeutics Inc.

Provide Quick Ratio
for TScan Therapeutics Inc.

Provide Current Ratio
for TScan Therapeutics Inc.

Provide Cash Ratio
for TScan Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for TScan Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for TScan Therapeutics Inc?

What is the current Free Cash Flow
of TScan Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for TScan Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
TScan Therapeutics Inc

Current Assets 299.5m
Cash & Short-Term Investments 297.7m
Other Current Assets 1.9m
Non-Current Assets 75.3m
Long-Term Investments 1.7m
PP&E 68.6m
Other Non-Current Assets 5m
Current Liabilities 38.6m
Accounts Payable 3.1m
Accrued Liabilities 14.2m
Other Current Liabilities 21.3m
Non-Current Liabilities 81.1m
Long-Term Debt 20.1m
Other Non-Current Liabilities 61m
Efficiency

Earnings Waterfall
TScan Therapeutics Inc

Revenue
12.2m USD
Operating Expenses
-123.8m USD
Operating Income
-111.6m USD
Other Expenses
7.2m USD
Net Income
-104.4m USD

Free Cash Flow Analysis
TScan Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

TCRX Profitability Score
Profitability Due Diligence

TScan Therapeutics Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
ROIC is Increasing
Negative 1-Year Revenue Growth
Declining ROE
17/100
Profitability
Score

TScan Therapeutics Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

TCRX Solvency Score
Solvency Due Diligence

TScan Therapeutics Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
53/100
Solvency
Score

TScan Therapeutics Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TCRX Price Targets Summary
TScan Therapeutics Inc

Wall Street analysts forecast TCRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TCRX is 12.82 USD with a low forecast of 10.1 USD and a high forecast of 15.75 USD.

Lowest
Price Target
10.1 USD
137% Upside
Average
Price Target
12.82 USD
201% Upside
Highest
Price Target
15.75 USD
270% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for TCRX?

Click here to dive deeper.

Dividends

TScan Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for TCRX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

TCRX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

TScan Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

225.5m USD

Dividend Yield

0%

Description

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. The company is headquartered in Waltham, Massachusetts and currently employs 104 full-time employees. The company went IPO on 2021-07-16. The firm is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The firm's lead liquid tumor TCR-T therapy candidates include TSC-100 and TSC-101, which are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation (HCT). TSC-100 and TSC-101 targets histocompatibility antigens (HA)-1 and HA-2 antigens, respectively. TScan solid tumor product candidates include TSC-200, TSC-201, TSC-202 and TSC-203. Its TSC-200 series of product candidates are being developed to treat both HPV-positive and HPV-negative tumors. The firm's platform technologies include TargetScan, ReceptorScan and T-Integrate.

Contact

MASSACHUSETTS
Waltham
830 Winter Street
+18573999500.0
www.tscan.com

IPO

2021-07-16

Employees

104

Officers

CEO & Director
Dr. Gavin MacBeath Ph.D.
Chief Legal & Strategy Officer and Company Secretary
Dr. Zoran Zdraveski J.D., Ph.D.
Co-Founder & Chairman of Scientific Advisory Board
Dr. Stephen J. Elledge Ph.D.
Co-Founder & Member of Advisory Board
Mr. Tomasz Kula Ph.D.
CFO & Treasurer
Mr. Jason A. Amello
Chief Technology Officer
Dr. Justin McCue Ph.D.
Show More
Senior Vice President of Human Resources
Ms. Ann Hargraves
Senior VP & Head of Translational Medicine
Dr. Shrikanta Chattopadhyay M.D.
Senior Vice President & Head of Quality
Mr. Ray Lockard M.B.A.
Senior VP & Head of Development Operations
Mr. Jim Murray
Show Less

See Also

Discover More
What is the Intrinsic Value of one TCRX stock?

The intrinsic value of one TCRX stock under the Base Case scenario is 1.53 USD.

Is TCRX stock undervalued or overvalued?

Compared to the current market price of 4.26 USD, TScan Therapeutics Inc is Overvalued by 64%.

Back to Top